Children’s National Hospital in Washington, D.C., has announced a $96 million investment from a donor who wishes to remain anonymous in support of rare pediatric brain tumor research and care.
One of the largest donations in the hospital’s history will enable it to recruit additional top talent and advance promising research. Specifically, the investment will fuel highly individualized, safer therapies including cellular immunotherapy, low-intensity focused ultrasound, neurosurgical innovation, and precision medicine. In addition, it will establish “gold standard” clinical care models, bolster programs that nurture patient and family well-being, and provide critical supports to the whole family.
According to Children’s National, brain tumors are the most common solid tumors affecting children, and as their brains are still developing, both the disease and current treatments can put them at risk for lifelong complications.
“This incredible partnership will lift up one of the nation’s top pediatric brain tumor programs into the stratosphere,” said Childrens National president and CEO Kurt Newman. “It will immediately propel our best-in-class research and care, allowing us to bring new therapies to children with brain tumors. This fundamentally changes the healthcare journey and long-term outcomes for children and their families.”
(Photo credit: Getty Images/Media Production)